Who is sponsoring NCT04132505?

NCT04132505 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT04132505?

Interventions in NCT04132505: Binimetinib, Hydroxychloroquine.

What condition does NCT04132505 study?

NCT04132505 studies Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8.

Is NCT04132505 still recruiting?

NCT04132505 is currently completed. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT04132505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Completed Phase 1 Last updated 6 April 2026

What this trial tests

Phase 1 trial testing Binimetinib in Metastatic Pancreatic Adenocarcinoma in 34 participants. Completed in 24 March 2026.

Timeline

22 October 2019

Primary endpoint
24 March 2026

24 March 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	22 October 2019
Primary completion	24 March 2026
Estimated completion	24 March 2026
Sites	1 location across United States

Drugs / interventions tested

Binimetinib (binimetinib) — full drug profile →
Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →

Conditions studied

Metastatic Pancreatic Adenocarcinoma — all drugs for Metastatic Pancreatic Adenocarcinoma →
Stage IV Pancreatic Cancer AJCC v8 — all drugs for Stage IV Pancreatic Cancer AJCC v8 →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Metastatic Pancreatic Adenocarcinoma or Stage IV Pancreatic Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine may prevent autophagy, a normal process in which a cell destroys proteins and other substances which may lead to cell death. Autophagy may prevent normal cells from developing into tumor cells, but it may also protect tumor cells by destroying anticancer drugs or substances taken up by them. Giving hydroxychloroquine together with binimetinib may work better in treating patients with pancreatic cancer compared to binimetinib alone.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.
Grossberg AJ, Chu LC, Deig CR, Fishman EK, et al · · 2020 · cited 368× · PMID 32683683 · DOI 10.3322/caac.21626
KRAS mutation in pancreatic cancer.
Luo J. · · 2021 · cited 279× · PMID 33676749 · DOI 10.1053/j.seminoncol.2021.02.003
Role of lysosomes in physiological activities, diseases, and therapy.
Zhang Z, Yue P, Lu T, Wang Y, et al · · 2021 · cited 238× · PMID 33990205 · DOI 10.1186/s13045-021-01087-1
The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.
Mukhopadhyay S, Vander Heiden MG, McCormick F. · · 2021 · cited 212× · PMID 33870211 · DOI 10.1038/s43018-021-00184-x
The multifaceted role of autophagy in cancer.
Russell RC, Guan KL. · · 2022 · cited 164× · PMID 35535466 · DOI 10.15252/embj.2021110031
Autophagy as a therapeutic target in pancreatic cancer.
Piffoux M, Eriau E, Cassier PA. · · 2021 · cited 148× · PMID 32929194 · DOI 10.1038/s41416-020-01039-5
The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy.
Yun CW, Jeon J, Go G, Lee JH, et al · · 2020 · cited 147× · PMID 33375363 · DOI 10.3390/ijms22010179
Harnessing metabolic dependencies in pancreatic cancers.
Encarnación-Rosado J, Kimmelman AC. · · 2021 · cited 143× · PMID 33742165 · DOI 10.1038/s41575-021-00431-7

Verify or expand the search:

Other trials of Binimetinib

Trials testing the same drug.

NCT05554354 — Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastat · Phase 2 · terminated
NCT05564403 — Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH T · Phase 2 · active not recruiting
NCT04870034 — Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic C · EARLY_PHASE1 · withdrawn
NCT05554367 — Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · Phase 2 · active not recruiting
NCT05304546 — Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma · Phase 2 · completed

Other recruiting trials for Metastatic Pancreatic Adenocarcinoma

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07226856 — BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P · Phase 2 · recruiting
NCT07189195 — TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory · Phase 1 · recruiting
NCT06396091 — A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer · Phase 1 · active not recruiting
NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04132505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04132505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing